The role of cannabinoids in neurodegenerative diseases

被引:51
作者
Glass, M [1 ]
机构
[1] Univ Auckland, Dept Pharmacol, Auckland 1, New Zealand
关键词
anandamide; 2-arachidonyl-glycerol; cannabinoid Huntington's disease; marijuana; multiple sclerosis; Parkinson's disease; schizophrenia; tremor;
D O I
10.1016/S0278-5846(01)00162-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
1. An understanding of the actions of Cannabis (Marijuana) has evolved from folklore to science over the previous hundred years. This progression was spurred by the discovery of an endogenous cannabinoid system consisting of two receptors and two endogenous ligands. 2. This system appears to be intricately involved in normal physiology, specifically in the control of movement, formation of memories and appetite control. As we are developing an increased understanding of the physiological role of endocannabinoids it is becoming clear that they may be involved in the pathology of several neurological diseases. 3. Furthermore an array of potential therapeutic targets is being determined - including specific cannabinoid agonists and antagonists as well as compounds that interrupt the synthesis, uptake or metabolism of the endocannabinoids. 4. This article reviews the recent progress in understanding the contribution of endocannabinoids to the pathology and therapy of Huntington's disease, Parkinson's disease, schizophrenia and tremor.
引用
收藏
页码:743 / 765
页数:23
相关论文
共 119 条
[81]   STRUCTURE OF A CANNABINOID RECEPTOR AND FUNCTIONAL EXPRESSION OF THE CLONED CDNA [J].
MATSUDA, LA ;
LOLAIT, SJ ;
BROWNSTEIN, MJ ;
YOUNG, AC ;
BONNER, TI .
NATURE, 1990, 346 (6284) :561-564
[82]   IDENTIFICATION OF AN ENDOGENOUS 2-MONOGLYCERIDE, PRESENT IN CANINE GUT, THAT BINDS TO CANNABINOID RECEPTORS [J].
MECHOULAM, R ;
BENSHABAT, S ;
HANUS, L ;
LIGUMSKY, M ;
KAMINSKI, NE ;
SCHATZ, AR ;
GOPHER, A ;
ALMOG, S ;
MARTIN, BR ;
COMPTON, DR ;
PERTWEE, RG ;
GRIFFIN, G ;
BAYEWITCH, M ;
BARG, J ;
VOGEL, Z .
BIOCHEMICAL PHARMACOLOGY, 1995, 50 (01) :83-90
[83]   ENANTIOMERIC CANNABINOIDS - STEREOSPECIFICITY OF PSYCHOTROPIC ACTIVITY [J].
MECHOULAM, R ;
FEIGENBAUM, JJ ;
LANDER, N ;
SEGAL, M ;
JARBE, TUC ;
HILTUNEN, AJ ;
CONSROE, P .
EXPERIENTIA, 1988, 44 (09) :762-764
[84]   EFFECT OF CANNABINOIDS ON SPASTICITY AND ATAXIA IN MULTIPLE-SCLEROSIS [J].
MEINCK, HM ;
SCHONLE, PW ;
CONRAD, B .
JOURNAL OF NEUROLOGY, 1989, 236 (02) :120-122
[85]   EFFECTS OF A CANNABINOID ON SPONTANEOUS AND EVOKED NEURONAL-ACTIVITY IN THE SUBSTANTIA-NIGRA PARS RETICULATA [J].
MILLER, AS ;
WALKER, JM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 279 (2-3) :179-185
[86]  
Müller-Vahl KR, 1999, MOVEMENT DISORD, V14, P1038, DOI 10.1002/1531-8257(199911)14:6<1038::AID-MDS1024>3.0.CO
[87]  
2-7
[88]   MOLECULAR CHARACTERIZATION OF A PERIPHERAL RECEPTOR FOR CANNABINOIDS [J].
MUNRO, S ;
THOMAS, KL ;
ABUSHAAR, M .
NATURE, 1993, 365 (6441) :61-65
[89]   CA-45 ACCUMULATION IN RAT-BRAIN AFTER CLOSED-HEAD INJURY - ATTENUATION BY THE NOVEL NEUROPROTECTIVE AGENT HU-211 [J].
NADLER, V ;
BIEGON, A ;
BEITYANNAI, E ;
ADAMCHIK, J ;
SHOHAMI, E .
BRAIN RESEARCH, 1995, 685 (1-2) :1-11
[90]  
Nagayama T, 1999, J NEUROSCI, V19, P2987